SEARCH:   Advanced

Blood, 15 July 2004, Vol. 104, No. 2, pp. 340-349. Prepublished online as a Blood First Edition Paper on March 30, 2004; DOI 10.1182/blood-2004-02-0518. This Article Full Text (PDF) All Versions of this Article: 2004-02-0518v1 104/2/340    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kaiser, T. Articles by Weissinger, E. M Search for Related Content PubMed PubMed Citation Articles by Kaiser, T. Articles by Weissinger, E. M Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 11, 2004 Accepted March 21, 2004 Proteomics applied to the clinical follow up of patients after allogeneic hematopoietic stem cell transplantation Thorsten Kaiser, Haytham Kamal, Andreas Rank, Hans-Jochem Kolb, Ernst Holler, Arnold Ganser, Bernd Hertenstein, Harald Mischak, and Eva M Weissinger* Mosaiques Diagnostics & Therapeutics AG, Hannover, Germany Dept. of Hematology/Oncology, Hannover Medical School, Hannover, Germany Jose-Carreras-Unit, Klinikum Grosshadern, Muenchen, Germany Dept. of Hematology, University of Regensburg, Regensburg, Germany Mosaiques Diagnostics & Therapeutics AG, Hannover, Germany; Dept. of Nephrology, Hannover Medical School, Hannover, Germany Mosaiques Diagnostics & Therapeutics AG, Hannover, Germany; Dept. of Hematology/Oncology, Hannover Medical School, Hannover, Germany * Corresponding author; email: eviweissinger{at}gmx.de. A phase 1 diagnostic study was performed to evaluate a novel technology for clinical proteom research based on capillary electrophoresis and mass spectrometry. Urine from 40 patients after hematopoietic stem cell transplantation (HSCT; 35 allogeneic; 5 autologous) and 5 patients with sepsis was collected for a period of 100 days and analyzed. More than 1000 different polypeptides could be detected in individual samples. Polypeptides-patterns excreted in the urine of patients were significantly different from those of healthy volunteers. No significant differences were detected comparing different conditioning regimens. The aim of this study was to identify polypeptides-patterns functioning as early indicators of graft versus host disease (GvHD). Eighteen patients developed GvHD after allogeneic HSCT. Sixteen differentially excreted polypeptides formed a pattern of early GvHD markers, allowing discrimination of GvHD from patients without complications with 82% specificity and 100% sensitivity, cross validated. Inclusion of 13 sepsis-specific polypeptides allowed to distinguish sepsis from GvHD with a specificity of 97% and a sensitivity of 100%. Sequencing 2 prominent GvHD-indicative polypeptides led to the identification of a peptide from leukotriene A4 hydrolase and a peptide from serum albumin. The data reveal that CE-MS allows identification of biomarkers for a variety of diseases or related complications. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Ravandi, A. Aribi, S. O'Brien, S. Faderl, D. Jones, A. Ferrajoli, X. Huang, S. York, S. Pierce, W. Wierda, et al. Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms J. Clin. Oncol., November 10, 2009; 27(32): 5425 - 5430. [Abstract] [Full Text] [PDF] G. Socie Graft-versus-host disease: proteomics comes of age Blood, January 8, 2009; 113(2): 271 - 272. [Full Text] [PDF] S. Paczesny, O. I. Krijanovski, T. M. Braun, S. W. Choi, S. G. Clouthier, R. Kuick, D. E. Misek, K. R. Cooke, C. L. Kitko, A. Weyand, et al. A biomarker panel for acute graft-versus-host disease Blood, January 8, 2009; 113(2): 273 - 278. [Abstract] [Full Text] [PDF] S. Decramer, A. G. de Peredo, B. Breuil, H. Mischak, B. Monsarrat, J.-L. Bascands, and J. P. Schanstra Urine in Clinical Proteomics Mol. Cell. Proteomics, October 1, 2008; 7(10): 1850 - 1862. [Abstract] [Full Text] [PDF] T. Hori, Y. Naishiro, H. Sohma, N. Suzuki, N. Hatakeyama, M. Yamamoto, T. Sonoda, Y. Mizue, K. Imai, H. Tsutsumi, et al. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease Blood, April 15, 2008; 111(8): 4403 - 4412. [Abstract] [Full Text] [PDF] E. M. Weissinger, E. Schiffer, B. Hertenstein, J. L. Ferrara, E. Holler, M. Stadler, H.-J. Kolb, A. Zander, P. Zurbig, M. Kellmann, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Blood, June 15, 2007; 109(12): 5511 - 5519. [Abstract] [Full Text] [PDF] D. Fliser, J. Novak, V. Thongboonkerd, A. Argiles, V. Jankowski, M. A. Girolami, J. Jankowski, and H. Mischak Advances in Urinary Proteome Analysis and Biomarker Discovery J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1057 - 1071. [Abstract] [Full Text] [PDF] A. Ganser, M. A. Morgan, and E. M. Weissinger Going from genes to proteins in myelodysplastic syndromes PNAS, January 23, 2007; 104(4): 1109 - 1110. [Full Text] [PDF] T. Pisitkun, R. Johnstone, and M. A. Knepper Discovery of Urinary Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1760 - 1771. [Abstract] [Full Text] [PDF] M. Mohty, D. Blaise, C. Faucher, N. Vey, R. Bouabdallah, A.-M. Stoppa, F. Viret, G. Gravis, D. Olive, and B. Gaugler Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation Blood, December 15, 2005; 106(13): 4407 - 4411. [Abstract] [Full Text] [PDF] J. Z. Haeggstrom Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis J. Biol. Chem., December 3, 2004; 279(49): 50639 - 50642. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020